Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes

Specific PHGKB|Cancer|PHGKB

Non-hodgkin Lymphoma Genomics

- Cancer PHGKB -

What's New

Last Posted: Feb 20, 2019

---

• Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.  
  Shin Seung-Ho et al. Leukemia & lymphoma 2019 Feb 1-10
• Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.  
  Galanina Natalie et al. Cancers 2018 Dec 11(1)
• Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.  
  Dunleavy Kieron et al. The Lancet. Haematology 2018 Dec 5(12) e609-e617
• Challenges and implications of genomics for T-cell lymphomas.  
  Jacobsen Eric D et al. Hematology. American Society of Hematology. Education Program 2018 Nov 2018(1) 63-68
• Genomics of aggressive B-cell lymphoma.  
  Rosenthal Allison et al. Hematology. American Society of Hematology. Education Program 2018 Nov 2018(1) 69-74
• Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.  
  Wu Fang-Tian et al. Annals of hematology 2018 Oct
• Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?  
  Davies Andrew et al. Hematology. American Society of Hematology. Education Program 2017 2017(1) 284-294
• The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.  
  de Mel Sanjay et al. International journal of molecular sciences 2018 Jun 19(7)
• Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.  
  Shu Wenying et al. Journal of clinical pharmacology 2017 Jul 57(7) 886-898
• Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.  
  Dubois Sydney et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Jun 22(12) 2919-28
• Precision Medicine for Diffuse Large B-cell Lymphoma.  
  Lim Megan S et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Jun 22(12) 2829-31
• The Promise and Challenges of CAR-T Gene Therapy.  
  Kuehn Bridget M et al. JAMA 2017 Nov
• Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.  
  Chen Qiushi et al. Leukemia & lymphoma 2017 Oct 1-10
• Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome.  
  Samadder N Jewel et al. JAMA oncology 2017 Aug
• BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.  
  Huet Sarah et al. American journal of hematology 2017 Jun 92(6) 515-519